US OptionsDetailed Quotes
ALT250509P7000
- 2.46
- 0.000.00%
15min DelayClose May 7 16:00 ET
0.00High0.00Low
2.46Open2.46Pre Close0 Volume1 Open Interest7.00Strike Price0.00Turnover612.51%IV15.30%PremiumMay 9, 2025Expiry Date1.64Intrinsic Value100Multiplier1DDays to Expiry0.82Extrinsic Value100Contract SizeAmericanOptions Type-0.6717Delta0.1643Gamma2.65Leverage Ratio-0.2652Theta-0.0002Rho-1.78Eff Leverage0.0013Vega
Altimmune Stock Discussion
Sign in to post a comment
$Sellas Life Sciences (SLS.US)$ (1.63) 1st alert
next one will be at 1.88 and too late
$Altimmune (ALT.US)$ 🥇🚀⏰
$MicroCloud Hologram (HOLO.US)$
Apextradez
next one will be at 1.88 and too late
$Altimmune (ALT.US)$ 🥇🚀⏰
$MicroCloud Hologram (HOLO.US)$
Apextradez
3
1
$Altimmune (ALT.US)$
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
$ParaZero Technologies (PRZO.US)$ Monthly Subscription dropped to 28.00 and yrly 220.00 However you decide you best get in asap the seats are filling up PRZo will SQUEEZE BIG you heard it here im done with Momo no one valuez winning here so all My X IG WB Fans have moved Apextradez is where goo gle it
$MicroCloud Hologram (HOLO.US)$ over 20 then 30 parabolic over 40 big things happening keep alert to $Altimmune (ALT.US)$ over 7 then double digits $Kindly MD (KDLY.US)$ wants ov...
$MicroCloud Hologram (HOLO.US)$ over 20 then 30 parabolic over 40 big things happening keep alert to $Altimmune (ALT.US)$ over 7 then double digits $Kindly MD (KDLY.US)$ wants ov...
Here are the levels to watch on this move down. Bouncing from 5.54 range so far. Watch for a retest of 5.80.
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
As i told yal several days ago, they are releasing results on two Third trials Today. The first one has been ongoing since 2021. The physical Human Results are being presented Today.
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
2
2
No comment yet
Magic 1983 : yes